Search

everythinglearnresearchcommunity

for

Search:↓

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Hairlines and hair loss treatments like finasteride and hair transplants. Celebrities' hairlines are discussed, noting genetics and interventions.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

RepliCel's potential hair loss treatment may cost around $1000 and aims to protect hair follicles from DHT, possibly reversing some miniaturization. It is not considered a cure and may be most effective in early hair loss stages, with its main advantage over finasteride being the lack of sexual side effects.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user compares using Minoxidil, finasteride, and RU58841 for hair loss to growing a Chia pet. They mention keeping their hair loss treatments private.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.

A user shared their journey from balding to using a hair system, expressing satisfaction with the results despite the costs. They mentioned trying finasteride but stopped due to side effects, and now enjoy increased attention from women with the hair system.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user has been using dutasteride, minoxidil, and RU58841 for two years but continues to experience excessive hair shedding, despite also taking various supplements and trying other treatments like red light therapy. They are seeking advice and sharing experiences with others facing similar hair loss challenges.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.

User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.